Determinants of adherence to obesity medication: A narrative review

IF 8 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Reviews Pub Date : 2025-01-20 DOI:10.1111/obr.13885

Arya M. Sharma, Susie Birney, Michael Crotty, Nick Finer, Gabriella Segal-Lieberman, Verónica Vázquez-Velázquez, Bernard Vrijens

{"title":"Determinants of adherence to obesity medication: A narrative review","authors":"Arya M. Sharma, Susie Birney, Michael Crotty, Nick Finer, Gabriella Segal-Lieberman, Verónica Vázquez-Velázquez, Bernard Vrijens","doi":"10.1111/obr.13885","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>The increasing prevalence of obesity, complex nature of this chronic disease, and risks of developing obesity-related comorbidities outline the need for sustainable and effective management for people living with obesity. In addition to behavioral interventions, obesity medications (OMs) are increasingly considered an integral part of management of people living with obesity. OM adherence is essential to achieve the health benefits of these medications. Adherence to medications, defined as the process by which patients take their medications as prescribed, is determined by a range of factors and can be broken down into phases: initiation, implementation, and persistence (the persistence phase includes discontinuation/stopping treatment). Obesity-specific challenges exist to optimize OM adherence, which may explain varying OM adherence compared with medication for other chronic diseases (diabetes, hypertension, dyslipidemia, and osteoporosis). However, lessons can be learned from other chronic diseases to improve OM adherence, for example from type 2 diabetes and hypertension. This review aims to provide practical guidance for identifying OM- and obesity-specific determinants of adherence and discusses adherence determinants per adherence phase and obesity management phase (weight gain, weight loss, and weight stabilization/regain). This practical guidance will assist with developing obesity-specific interventions to improve OM adherence.</p>\n </section>\n \n <section>\n \n <h3> Practitioner Points</h3>\n \n <div>\n \n <ul>\n \n <li>OMs are increasingly considered as an integral part of obesity management; however, like with all chronic disease medications, low adherence to these medications is often observed, impacting their therapeutic effect.</li>\n \n <li>Adherence to obesity medication can be affected at any phase of obesity management (weight gain, weight loss, and weight stabilization/regain) so considering the disease phase can help identify potential reasons for low adherence.</li>\n \n <li>Future initiatives to improve adherence to obesity medication should be a key focus of discussions at each opportunity with healthcare professionals, including thorough evaluation and targeted education, all in a supportive and stigma-free manner.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":"26 5","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/obr.13885","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/obr.13885","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

The increasing prevalence of obesity, complex nature of this chronic disease, and risks of developing obesity-related comorbidities outline the need for sustainable and effective management for people living with obesity. In addition to behavioral interventions, obesity medications (OMs) are increasingly considered an integral part of management of people living with obesity. OM adherence is essential to achieve the health benefits of these medications. Adherence to medications, defined as the process by which patients take their medications as prescribed, is determined by a range of factors and can be broken down into phases: initiation, implementation, and persistence (the persistence phase includes discontinuation/stopping treatment). Obesity-specific challenges exist to optimize OM adherence, which may explain varying OM adherence compared with medication for other chronic diseases (diabetes, hypertension, dyslipidemia, and osteoporosis). However, lessons can be learned from other chronic diseases to improve OM adherence, for example from type 2 diabetes and hypertension. This review aims to provide practical guidance for identifying OM- and obesity-specific determinants of adherence and discusses adherence determinants per adherence phase and obesity management phase (weight gain, weight loss, and weight stabilization/regain). This practical guidance will assist with developing obesity-specific interventions to improve OM adherence.

Practitioner Points

OMs are increasingly considered as an integral part of obesity management; however, like with all chronic disease medications, low adherence to these medications is often observed, impacting their therapeutic effect.
Adherence to obesity medication can be affected at any phase of obesity management (weight gain, weight loss, and weight stabilization/regain) so considering the disease phase can help identify potential reasons for low adherence.
Future initiatives to improve adherence to obesity medication should be a key focus of discussions at each opportunity with healthcare professionals, including thorough evaluation and targeted education, all in a supportive and stigma-free manner.

Abstract Image

查看原文本刊更多论文

依从性肥胖药物的决定因素：叙述性回顾。

肥胖的日益流行、这种慢性疾病的复杂性以及与肥胖相关的合并症的风险，都表明需要对肥胖患者进行可持续和有效的管理。除了行为干预外，肥胖药物（OMs）越来越被认为是肥胖患者管理的一个组成部分。遵守OM对于实现这些药物的健康益处至关重要。药物依从性，定义为患者按处方服药的过程，由一系列因素决定，可分为几个阶段：开始、实施和持续（持续阶段包括停药/停止治疗）。肥胖特有的挑战存在于优化OM依从性，这可以解释与其他慢性疾病（糖尿病、高血压、血脂异常和骨质疏松症）的药物治疗相比，OM依从性的差异。但是，可以从其他慢性病中吸取经验教训，例如从2型糖尿病和高血压中吸取经验教训。本综述旨在为确定坚持治疗的OM和肥胖特异性决定因素提供实用指导，并讨论每个坚持治疗阶段和肥胖管理阶段（体重增加、体重减轻和体重稳定/恢复）的坚持治疗决定因素。本实用指南将有助于制定针对肥胖的干预措施，以提高OM的依从性。医生观点：OMs越来越被认为是肥胖管理的重要组成部分；然而，与所有慢性病药物一样，经常观察到这些药物的低依从性，影响其治疗效果。在肥胖管理的任何阶段（体重增加、体重减轻和体重稳定/恢复），坚持服用减肥药都可能受到影响，因此考虑疾病阶段可以帮助确定低依从性的潜在原因。未来提高肥胖药物依从性的举措应该是每次与医疗保健专业人员讨论的重点，包括彻底的评估和有针对性的教育，所有这些都以支持和无耻辱感的方式进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Reviews 医学-内分泌学与代谢

CiteScore

19.30

自引率

1.10%

发文量

130

审稿时长

1 months

期刊介绍： Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities. Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.